Solan. Himachal produces medicines worth Rs 40 thousand crores every year. Himachal including Baddi has a 12 percent share in the country's total medicine business. If the central government supports, then by 2028, medicines will be produced in India as per the standards of European countries.

The World Health Organization (WHO) has implemented Revised Schedule M to improve drug production worldwide, which India's pharma sector is trying to adopt. If collateral free loans (without pledging anything) are made available by the government, the pharma sector will get new energy.

India produces medicines worth three lakh crore rupees every year. Nearly 10 thousand pharma industries export medicines all over the world. In India, one and a half lakh.

675 industries are established in Baddi

At present, 675 industries are established in Baddi, Himachal Pradesh. Many famous pharma industries are established including Abbott Healthcare, Cipla Pharma, Glenmark, Ranbaxy, Dr. Reddy, Sun Pharma, Pinnacle Life Science, Park Pharmaceutical, Tark, Scott Edil, Emily, Tarrant, Alchem ​​Lab. 35 percent of the medicines manufactured in the state are exported, which are sent to more than 150 countries. 65 percent of the medicines are being used in different states of India.

Main demands of pharma entrepreneurs

• Pharma entrepreneurs are seeking collateral-free loans for Revised Schedule M and other upgradations.
• After the implementation of GST, all states have the same tax system. In such a situation, the hill states are expecting a special package.
• The work of railway extension to pharma industries should be completed as soon as possible.
• Transportation is expensive in Himachal, the Centre should give subsidy in income tax.

What is Revised Schedule M

The revised Schedule M is a part of the Drugs and Cosmetics Act, 1945. It lays down requirements for good manufacturing practices (GMP) and premises, plant, and equipment for pharmaceutical products. The Union Health Ministry had notified the revised rules on January 6. The aim of these rules is to ensure robust quality control for pharma and biopharmaceutical products.